Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform rating and announces Price Target of $98.